CN101087593A - 含可溶性粘合剂的结肠泻药组成物 - Google Patents
含可溶性粘合剂的结肠泻药组成物 Download PDFInfo
- Publication number
- CN101087593A CN101087593A CNA2004800407012A CN200480040701A CN101087593A CN 101087593 A CN101087593 A CN 101087593A CN A2004800407012 A CNA2004800407012 A CN A2004800407012A CN 200480040701 A CN200480040701 A CN 200480040701A CN 101087593 A CN101087593 A CN 101087593A
- Authority
- CN
- China
- Prior art keywords
- prescription
- cathartic
- colon
- sodium
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 239000008141 laxative Substances 0.000 title claims abstract description 27
- 239000011230 binding agent Substances 0.000 title claims description 52
- 230000000112 colonic effect Effects 0.000 title abstract description 27
- 230000001543 purgative effect Effects 0.000 title abstract description 3
- 210000001072 colon Anatomy 0.000 claims abstract description 122
- 239000000470 constituent Substances 0.000 claims description 57
- 239000003826 tablet Substances 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 42
- 239000001488 sodium phosphate Substances 0.000 claims description 38
- 235000011008 sodium phosphates Nutrition 0.000 claims description 38
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 31
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 31
- 229960003339 sodium phosphate Drugs 0.000 claims description 31
- 206010010774 Constipation Diseases 0.000 claims description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims description 23
- 230000002475 laxative effect Effects 0.000 claims description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 17
- 230000000968 intestinal effect Effects 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 230000003204 osmotic effect Effects 0.000 claims description 13
- 239000000314 lubricant Substances 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 11
- 210000000936 intestine Anatomy 0.000 claims description 11
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 10
- 235000019800 disodium phosphate Nutrition 0.000 claims description 10
- 210000003608 fece Anatomy 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 9
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 7
- 229960005132 cisapride Drugs 0.000 claims description 7
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 7
- GOZDTZWAMGHLDY-UHFFFAOYSA-L sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 claims description 7
- 229960005077 sodium picosulfate Drugs 0.000 claims description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- MUVQKFGNPGZBII-UHFFFAOYSA-N 1-anthrol Chemical class C1=CC=C2C=C3C(O)=CC=CC3=CC2=C1 MUVQKFGNPGZBII-UHFFFAOYSA-N 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 206010047700 Vomiting Diseases 0.000 claims description 6
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 claims description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 6
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 6
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 claims description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical group [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 6
- 230000008673 vomiting Effects 0.000 claims description 6
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 5
- 229960005249 misoprostol Drugs 0.000 claims description 5
- 239000012188 paraffin wax Substances 0.000 claims description 5
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 5
- 229960002876 tegaserod Drugs 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 206010046814 Uterine prolapse Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
- 229940056211 paraffin Drugs 0.000 claims description 4
- 208000013823 pelvic organ prolapse Diseases 0.000 claims description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 4
- 235000011152 sodium sulphate Nutrition 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 claims description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 3
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 claims description 3
- 241001116389 Aloe Species 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 3
- 150000004056 anthraquinones Chemical class 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229960002997 dehydrocholic acid Drugs 0.000 claims description 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 3
- 229960000878 docusate sodium Drugs 0.000 claims description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 3
- 239000000347 magnesium hydroxide Substances 0.000 claims description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 3
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 3
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 3
- 239000004137 magnesium phosphate Substances 0.000 claims description 3
- 229960002261 magnesium phosphate Drugs 0.000 claims description 3
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 229940125725 tranquilizer Drugs 0.000 claims description 3
- 239000003204 tranquilizing agent Substances 0.000 claims description 3
- 230000002936 tranquilizing effect Effects 0.000 claims description 3
- CPUHNROBVJNNPW-VVBPCJSVSA-N (10r)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2r,3r,4r,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-10h-anthracen-9-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-VVBPCJSVSA-N 0.000 claims description 2
- IPQVTOJGNYVQEO-UHFFFAOYSA-N 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical class OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2C1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(OC3C(C(O)C(O)C(CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-UHFFFAOYSA-N 0.000 claims description 2
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 claims description 2
- 206010002153 Anal fissure Diseases 0.000 claims description 2
- 208000016583 Anus disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 206010057669 Colon injury Diseases 0.000 claims description 2
- 208000009531 Fissure in Ano Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 206010029897 Obsessive thoughts Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010072587 Rectal injury Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000003679 aging effect Effects 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 229940069428 antacid Drugs 0.000 claims description 2
- 239000003159 antacid agent Substances 0.000 claims description 2
- 230000001458 anti-acid effect Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 229960000503 bisacodyl Drugs 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 229940071711 casanthranol Drugs 0.000 claims description 2
- 210000000589 cicatrix Anatomy 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims description 2
- 229940018602 docusate Drugs 0.000 claims description 2
- 230000035622 drinking Effects 0.000 claims description 2
- 208000014617 hemorrhoid Diseases 0.000 claims description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 208000003532 hypothyroidism Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 229960002337 magnesium chloride Drugs 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 229960000816 magnesium hydroxide Drugs 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 229960003390 magnesium sulfate Drugs 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 229940095060 magnesium tartrate Drugs 0.000 claims description 2
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 claims description 2
- 230000008855 peristalsis Effects 0.000 claims description 2
- 229960005382 phenolphthalein Drugs 0.000 claims description 2
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 claims description 2
- 230000035935 pregnancy Effects 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 229930186851 sennoside Natural products 0.000 claims description 2
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 claims description 2
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 2
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 claims description 2
- 229960003010 sodium sulfate Drugs 0.000 claims description 2
- 239000001433 sodium tartrate Substances 0.000 claims description 2
- 229960002167 sodium tartrate Drugs 0.000 claims description 2
- 235000011004 sodium tartrates Nutrition 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 244000134552 Plantago ovata Species 0.000 claims 3
- 235000003421 Plantago ovata Nutrition 0.000 claims 3
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 2
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 239000009223 Psyllium Substances 0.000 claims 1
- 235000021282 Sterculia Nutrition 0.000 claims 1
- 241001503664 Sterculia nobilis Species 0.000 claims 1
- 240000001058 Sterculia urens Species 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 229940070687 psyllium Drugs 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 229940059107 sterculia Drugs 0.000 claims 1
- 239000000853 adhesive Substances 0.000 abstract 4
- 230000001070 adhesive effect Effects 0.000 abstract 4
- 238000012800 visualization Methods 0.000 abstract 2
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 229940111504 visicol Drugs 0.000 description 35
- 238000002052 colonoscopy Methods 0.000 description 30
- 230000001225 therapeutic effect Effects 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 238000004140 cleaning Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 13
- 210000001815 ascending colon Anatomy 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000035568 catharsis Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 241000883990 Flabellum Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- -1 Polyethylene Polymers 0.000 description 5
- 229910000831 Steel Inorganic materials 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000010959 steel Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- PLZNPHDJGFDNRM-UHFFFAOYSA-M O.[Na+].[O-][PH2]=O Chemical compound O.[Na+].[O-][PH2]=O PLZNPHDJGFDNRM-UHFFFAOYSA-M 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000001839 endoscopy Methods 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000012943 hotmelt Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000000799 cathartic agent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010665 pine oil Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000009478 high shear granulation Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 2
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000990027 Bisaltes Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 239000010369 Cascara Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241001428166 Eucheuma Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000556215 Frangula purshiana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- YAVVGPBYBUYPSR-UHFFFAOYSA-N benzene;oxygen Chemical compound [O].C1=CC=CC=C1 YAVVGPBYBUYPSR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229940058505 cascara Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229960001577 dantron Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000008144 emollient laxative Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940031958 magnesium carbonate hydroxide Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001479 sodium magnesium phosphate Inorganic materials 0.000 description 1
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Abstract
Description
成分 | 功能 | 用量重量% |
磷酸二氢钠,活性 | 活性 | 45.00至75.00 |
磷酸氢二钠,活性 | 活性 | 15.00至30.00 |
PEG-8000 | 粘合剂 | 5.00至20.00 |
硬脂酸镁 | 润滑剂 | 0.10至1.50 |
成分 | 功能 | Diacol用量重量% | Visicol用量重量% |
磷酸二氢钠,活性 | 活性 | 55.10 | 62.44 |
磷酸氢二钠,活性 | 活性 | 19.90 | 22.55 |
微晶性纤维素 | 粘合剂 | 23.00 | 13.00 |
胶质二氧化硅 | 稀释剂 | 0.50 | 0.50 |
硬脂酸镁 | 润滑剂 | 1.50 | 1.50 |
总量 | 100 | 100 |
成分 | 功能 | 用量重量% | 用量/药剂形态(毫克) | 用量/批(公斤) |
磷酸二氢钠,活性 | 活性 | 65.75 | 1102.0 | 295.9 |
磷酸氢二钠,活性 | 活性 | 23.75 | 398.0 | 106.9 |
PEG-8000 | 粘合剂 | 10.00 | 167.6 | 45.0 |
硬脂酸镁 | 润滑剂 | 0.50 | 8.4 | 2.26 |
总量 | 100 | 1676.0 | 450.06 |
Diacol | Visicol | INKP-102 | |
粘合剂的量 | 23% | 13% | 10% |
粘合剂 | MCC | MCC | PEG |
片剂尺寸 | 0.950×0.406吋 | 0.850×0.352吋 | 0.750×0.40吋 |
厚度:6.72毫米 | 厚度:7.12毫米 | 厚度:6.86毫米 | |
片剂性质 | 大、干且难以吞咽 | 大、干且难以吞咽 | 小、滑且易于吞咽 |
重量(毫克) | 2000.0 | 1764.8 | 1676.0 |
崩解时间 | 约31分钟 | 约25分钟 | 约11分钟 |
成分 | 功能 | 用量重量% |
磷酸二氢钠,活性 | 活性 | 65.73% |
磷酸氢二钠,活性 | 活性 | 23.74% |
吡啶亚甲双芬酯 | 活性 | 0.03% |
PEG-8000 | 粘合剂 | 10.00 |
硬脂酸镁 | 润滑剂 | 0.50 |
总量 | 100 |
治疗方式 | 配量指示 |
A | 40个Visicol片剂(60公克磷酸钠)经口服用如下:在结肠镜检查前一个晚上6点开始历经1.5小时20锭,以及在结肠镜检查前3至5小时开始历经1.5小时20锭,而片剂配合至少8盎斯澄净液体每15分钟一次服用3个。(如经认证的说明的建议) |
B | 40个INKP-102片剂(60公克磷酸钠)经口服用如下:在结肠镜检查前一个晚上6点开始历经1.5小时20锭,以及在结肠镜检查前3至5小时开始历经1.5小时20锭,而片剂配合至少8盎斯澄净液体每15分钟一次服用3个。 |
C | 40个INKP-102片剂(60公克磷酸钠)经口服用如下:在结肠镜检查前一个晚上6点开始历经1小时20锭,以及在结肠镜检查前3至5小时开始历经1小时20锭,而片剂配合至少8盎斯澄净液体每15分钟一次服用4个。 |
D | 32个INKP-102片剂(48公克磷酸钠)经口服用如下:在结肠镜检查前一个晚上6点开始历经1小时20锭,以及在同一个晚上10点开始历经半小时12锭,而片剂配合至少8盎斯澄净液体每15分钟一次服用4个。在结肠镜检查当天不服用片剂。 |
E | 32个INKP-102片剂(48公克磷酸钠)经口服用如下:在结肠镜检查前一个晚上6点开始历经1小时20锭,以及在结肠镜检查前3至5小时开始历经半小时12锭,而片剂配合至少8盎斯澄净液体每15分钟一次服用4个。 |
F | 28个INKP-102片剂(42公克磷酸钠)经口服用如下:在结肠镜检查前一个晚上6点开始历经1小时20锭,以及在同一个晚上9点开始历经15分钟8锭,而片剂配合至少8盎斯澄净液体每15分钟一次服用4个。 |
G | 28个INKP-102片剂(42公克磷酸钠)经口服用如下:在结肠镜检查前一个晚上6点开始20锭,以及隔天在结肠镜检查前3至5小时开始8锭,而片剂配合至少8盎斯澄净液体每15分钟一次服用4个。 |
参数 | Visicol | INKP-102治疗族群 | 所有患者(n=214) | |||||
40锭(60公克) | 40锭(60公克) | 32锭(48公克) | 28锭(42公克) | |||||
A | B | C | D | E | F | G | ||
每剂3锭(n=29) | 每剂3锭(n=32) | 每剂4锭(n=29) | 每剂4锭(n=30) | 每剂4锭(n=33) | 每剂4锭(n=32) | 每剂4锭(n=29) | ||
n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
优异 | 14(48) | 24(75) | 22(76) | 18(60) | 26(79) | 15(47) | 22(76) | 141(66) |
良好 | 11(38) | 7(22) | 7(24) | 9(30) | 6(18) | 8(25) | 4(14) | 52(24) |
普通 | 4(14) | 1(3) | 0(0) | 1(3) | 1(3) | 5(16) | 2(7) | 14(7) |
不适当 | 0(0) | 0(0) | 0(0) | 2(7) | 0(0) | 4(13) | 1(3) | 7(3) |
平均 | 1.66 | 1.28 | 1.24 | 1.57 | 1.24 | 1.94 | 1.38 | 1.47 |
标准偏差 | 0.72 | 0.52 | 0.44 | 0.86 | 0.50 | 1.08 | 0.78 | 0.76 |
P-值* | 未测定 | 0.0472 | 0.0322 | 0.6422 | 0.0275 | 0.1332 | 0.1519 | 未测定 |
参数 | Visicol | INKP-102治疗族群 | 所有患者(n=214) | |||||
40锭(60公克) | 40锭(60公克) | 32锭(48公克) | 28锭(42公克) | |||||
A | B | C | D | E | F | G | ||
每剂3锭(n=29) | 每剂3锭(n=32) | 每剂4锭(n=29) | 每剂4锭(n=30) | 每剂4锭(n=33) | 每剂4锭(n=32) | 每剂4锭(n=29) | ||
n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
优异 | 11(38) | 24(75) | 21(72) | 15(50) | 27(82) | 15(47) | 20(69) | 133(62) |
良好 | 12(41) | 7(22) | 7(24) | 5(17) | 6(18) | 7(22) | 6(21) | 50(23) |
普通 | 5(17) | 1(3) | 0(0) | 8(27) | 0(0) | 6(19) | 2(7) | 22(10) |
不适当 | 0(0) | 0(0) | 0(0) | 1(3) | 0(0) | 4(13) | 1(3) | 6(3) |
平均 | 1.79 | 1.28 | 1.25 | 1.83 | 1.18 | 1.97 | 1.45 | 1.53 |
标准偏差 | 0.74 | 0.52 | 0.44 | 0.97 | 0.39 | 1.09 | 0.78 | 0.79 |
P-值* | 未测定 | 0.0097 | 0.0078 | 0.8325 | 0.0019 | 0.3444 | 0.0894 | 未测定 |
参数 | Visicol | INKP-102治疗族群 | 所有患者(n=214) | |||||
40锭(60公克) | 40锭(60公克) | 32锭(48公克) | 28锭(42公克) | |||||
A | B | C | D | E | F | G | ||
每剂3锭(n=29) | 每剂3锭(n=32) | 每剂4锭(n=29) | 每剂4锭(n=30) | 每剂4锭(n=33) | 每剂4锭(n=32) | 每剂4锭(n=29) | ||
n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
优异 | 20(69) | 28(88) | 24(83) | 19(63) | 29(88) | 16(50) | 24(83) | 160(75) |
良好 | 6(21) | 3(9) | 5(17) | 7(23) | 4(12) | 8(25) | 2(7) | 35(16) |
普通 | 3(10) | 1(3) | 0(0) | 0 | 0(0) | 5(16) | 2(7) | 13(6) |
不适当 | 0(0) | 0(0) | 0(0) | 2(7) | 0(0) | 3(9) | 1(3) | 6(3) |
平均 | 1.41 | 1.16 | 1.17 | 1.57 | 1.12 | 1.84 | 1.31 | 1.37 |
标准偏差 | 0.68 | 0.45 | 0.38 | 0.90 | 0.33 | 1.02 | 0.76 | 0.72 |
P-值* | 未测定 | 0.1473 | 0.1846 | 0.3962 | 0.0975 | 0.0160 | 0.5690 | 未测定 |
Visicol | INKP-102治疗族群 |
参数 | 40锭(60公克) | 40锭(60公克) | 32锭(48公克) | 28锭(42公克) | 所有患者(n=214) | |||
A | B | C | D | E | F | G | ||
每剂3锭(n=29) | 每剂3锭(n=32) | 每剂4锭(n=29) | 每剂4锭(n=30) | 每剂4锭(n=33) | 每剂4锭(n=32) | 每剂4锭(n=29) | ||
n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
优异 | 16(55) | 27(84) | 23(79) | 17(57) | 30(91) | 15(47) | 22(76) | 150(70) |
良好 | 7(24) | 4(13) | 5(17) | 3(10) | 3(9) | 8(25) | 4(14) | 34(16) |
普通 | 4(14) | 1(3) | 0(0) | 8(27) | 0(0) | 5(16) | 2(7) | 20(9) |
不适当 | 0(0) | 0(0) | 0(0) | 1(3) | 0(0) | 4(13) | 1(3) | 6(3) |
平均 | 1.58 | 1.19 | 1.18 | 1.76 | 1.09 | 1.94 | 1.38 | 1.44 |
标准偏差 | 0.75 | 0.47 | 0.39 | 0.99 | 0.29 | 1.08 | 0.78 | 0.78 |
P-值* | 未测定 | 0.0553 | 0.0572 | 0.3000 | 0.0151 | 0.0468 | 0.3682 | 未测定 |
参数 | Visicol | INKP-102治疗族群 | 所有患者(n=214) | |||||
40锭(60公克) | 40锭(60公克) | 32锭(48公克) | 28锭(42公克) | |||||
A | B | C | D | E | F | G | ||
每剂3锭(n=29) | 每剂3锭(n=32) | 每剂4锭(n=29) | 每剂4锭(n=30) | 每剂4锭(n=33) | 每剂4锭(n=32) | 每剂4锭(n=29) | ||
n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
反应体 | 25(86) | 31(79) | 29(100) | 27(90) | 32(97) | 23(72) | 26(90) | 193(90) |
非反应体 | 4(14) | 1(3) | 0(0) | 3(10) | 1(3) | 9(28) | 3(10) | 21(10) |
P-值* | 未测定 | 0.1816 | 0.1120 | 0.7065 | 0.1762 | 0.2192 | >0.9999 | 未测定 |
参数 | Visicol | INKP-102治疗族群 | 所有患者(n=214) | |||||
40锭(60公克) | 40锭(60公克) | 32锭(48公克) | 28锭(42公克) | |||||
A | B | C | D | E | F | G | ||
每剂3锭(n=29) | 每剂3锭(n=32) | 每剂4锭(n=29) | 每剂4锭(n=30) | 每剂4淀(n=33) | 每剂4锭(n=32) | 每剂4锭(n=29) | ||
n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
反应体 | 26(90) | 31(97) | 29(100) | 26(87) | 33(100) | 24(75) | 26(90) | 195(91) |
非反应体 | 3(10) | 1(3) | 0(0) | 4(13) | 0(0) | 8(25) | 3(10) | 19(9) |
P-值* | 未测定 | 0.3385 | 0.2368 | >0.9999 | 0.0966 | 0.1884 | >0.9999 | 未测定 |
Claims (37)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210119344.5A CN102648980B (zh) | 2003-11-19 | 2004-11-17 | 含可溶性粘合剂的结肠泻药组成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52314203P | 2003-11-19 | 2003-11-19 | |
US60/523,142 | 2003-11-19 | ||
PCT/US2004/038220 WO2005051361A1 (en) | 2003-11-19 | 2004-11-17 | Colonic purgative composition with soluble binding agent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210119344.5A Division CN102648980B (zh) | 2003-11-19 | 2004-11-17 | 含可溶性粘合剂的结肠泻药组成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101087593A true CN101087593A (zh) | 2007-12-12 |
CN101087593B CN101087593B (zh) | 2013-07-17 |
Family
ID=34632758
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800407012A Active CN101087593B (zh) | 2003-11-19 | 2004-11-17 | 含可溶性粘合剂的结肠泻药组成物 |
CN201210119344.5A Active CN102648980B (zh) | 2003-11-19 | 2004-11-17 | 含可溶性粘合剂的结肠泻药组成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210119344.5A Active CN102648980B (zh) | 2003-11-19 | 2004-11-17 | 含可溶性粘合剂的结肠泻药组成物 |
Country Status (12)
Country | Link |
---|---|
US (3) | US7687075B2 (zh) |
EP (2) | EP1682098B1 (zh) |
JP (3) | JP5329042B2 (zh) |
KR (4) | KR101323628B1 (zh) |
CN (2) | CN101087593B (zh) |
AR (1) | AR046651A1 (zh) |
AU (2) | AU2004292428B2 (zh) |
BR (2) | BRPI0416702B8 (zh) |
CA (2) | CA2814523C (zh) |
ES (1) | ES2584866T3 (zh) |
PL (1) | PL1682098T3 (zh) |
WO (1) | WO2005051361A1 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101874796A (zh) * | 2009-04-29 | 2010-11-03 | 田普森 | 一种治疗便秘的药物制剂及其制备方法 |
CN102178694A (zh) * | 2011-05-06 | 2011-09-14 | 四川健能制药有限公司 | 磷酸钠盐液体制剂 |
CN102283861A (zh) * | 2010-06-17 | 2011-12-21 | 杭州赛利药物研究所有限公司 | 氢氧化镁在制药中的用途以及氢氧化镁制剂和制备方法 |
CN103585173A (zh) * | 2013-10-28 | 2014-02-19 | 王显著 | 含硫酸钠和匹可硫酸的药物组合物 |
CN105228634A (zh) * | 2013-05-17 | 2016-01-06 | 协和化学工业株式会社 | 用于大肠检查或手术的处理剂和处理方法 |
CN107787223A (zh) * | 2015-06-22 | 2018-03-09 | 西梯茜生命工学股份有限公司 | 肠道清洁用泻剂组合物 |
US9919007B2 (en) | 2013-03-15 | 2018-03-20 | Braintree Laboratories, Inc. | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof |
CN108601842A (zh) * | 2016-01-28 | 2018-09-28 | 西梯茜生命工学股份有限公司 | 泻药组合物 |
US10143656B1 (en) | 2017-08-04 | 2018-12-04 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
CN112386577A (zh) * | 2019-08-16 | 2021-02-23 | 北京天衡药物研究院有限公司 | 一种治疗便秘的组合物 |
CN112587498A (zh) * | 2020-12-29 | 2021-04-02 | 哈尔滨瀚钧现代制药有限公司 | 多库酯钠丹蒽醌及其制备方法 |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0224909D0 (en) * | 2002-10-25 | 2002-12-04 | Norgine Europe Bv | Colon cleansing compositions |
US7687075B2 (en) | 2003-11-19 | 2010-03-30 | Salix Pharmaceuticals, Ltd. | Colonic purgative composition with soluble binding agent |
GB0409104D0 (en) * | 2004-04-23 | 2004-05-26 | Norgine Europe Bv | Compressed pharmaceutical compositions |
EP1835854A4 (en) * | 2004-12-30 | 2008-03-05 | Given Imaging Ltd | DEVICE, SYSTEM AND METHOD FOR THE INVESTIGATION IN VIVO |
EP2676667A1 (en) * | 2005-05-06 | 2013-12-25 | Salix Pharmaceuticals, Inc. | Polyethylene glycol colonic purgative composition |
AU2013202513B2 (en) * | 2005-05-06 | 2016-03-24 | Salix Pharmaceuticals, Inc. | Polyethylene glycol colonic purgative composition |
CN1748675A (zh) * | 2005-07-11 | 2006-03-22 | 丛晓东 | 大黄酸类化合物的复合物及制备方法与治疗糖尿病的应用 |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
TW200816983A (en) * | 2006-04-07 | 2008-04-16 | Sunten Phytotech Co Ltd | Anthracenedione compounds |
DE102006017672B4 (de) * | 2006-04-12 | 2008-07-03 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Zusammensetzung zur Verwendung als Laxativum |
ES2292345B1 (es) * | 2006-05-12 | 2009-02-16 | Madaus, S.A. | "uso, composicion y preparacion farmaceutica de plantago ovata". |
DE102007023397B4 (de) * | 2007-05-02 | 2015-03-26 | Madaus Gmbh | Neue pharmazeutische Zusammensetzung zur Verwendung als Laxativum |
EP2160188A2 (en) * | 2007-05-17 | 2010-03-10 | Theravance, Inc. | Prokinetic agent for bowel preparation |
NZ580999A (en) * | 2007-05-17 | 2012-05-25 | David Lubowski | Combination laxative compositions comprising a colonic stimulant and a bulking laxative |
CN101450049A (zh) * | 2007-12-07 | 2009-06-10 | 辉凌国际制药(瑞士)有限公司 | 药物组合物 |
EP2294012B1 (en) * | 2008-05-07 | 2014-07-09 | Salix Pharmaceuticals, Ltd. | Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease |
WO2010005965A1 (en) * | 2008-07-08 | 2010-01-14 | Aronchick Craig A | Colonic purgative formulations and methods of using the same |
KR101053731B1 (ko) * | 2008-10-21 | 2011-08-02 | 이문성 | 용해시간 조절형 장세척제 조성물의 제조방법 |
US20100178360A1 (en) * | 2009-01-13 | 2010-07-15 | Universite Libre De Bruxelles | Nutritive composition |
CA2757226A1 (en) * | 2009-03-27 | 2010-09-30 | Salix Pharmaceuticals, Ltd. | Compositions for bowel preparation and methods of use thereof |
EP2421373B1 (en) * | 2009-04-21 | 2019-09-18 | Dale R. Bachwich | Colon lavage system |
US8470983B2 (en) * | 2009-06-03 | 2013-06-25 | Aptalis Pharma Canada Inc. | L-sugar colon cleansing agent and uses thereof |
US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
US20110021591A1 (en) * | 2009-07-21 | 2011-01-27 | Gordon Douglas J | Phenylbutazone carrier formulation showing increased bioactivity in animals |
TW201113366A (en) | 2009-08-31 | 2011-04-16 | Zeria Pharm Co Ltd | Orally administrable tablet for intestinal lavage |
WO2011047178A1 (en) * | 2009-10-14 | 2011-04-21 | Gi Innovation, Pllc | Colon cleansing of residual stool and secretions during colonoscopy |
AU2010312309B2 (en) | 2009-10-26 | 2016-10-06 | Thomas Julius Borody | Novel enteric combination therapy |
MX355760B (es) * | 2010-12-13 | 2018-04-27 | Salix Pharmaceuticals Inc | Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas. |
KR20140012980A (ko) | 2011-01-28 | 2014-02-04 | 윌리엄 에이. 셰버 | 장 세척용 방법, 조성물 및 패키지 |
TWI535461B (zh) | 2011-03-11 | 2016-06-01 | 諾金私人有限公司 | 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法 |
US8778907B2 (en) | 2011-04-27 | 2014-07-15 | Cumberland Pharmaceuticals | Lactulose for bowel evacuation |
JP5842521B2 (ja) * | 2011-09-30 | 2016-01-13 | ゼリア新薬工業株式会社 | 便秘改善薬 |
JP6240610B2 (ja) * | 2011-10-27 | 2017-11-29 | サリックス ファーマシューティカルズ,インコーポレイテッド | 電解質下剤 |
RU2473330C1 (ru) * | 2011-12-09 | 2013-01-27 | Александр Павлович Погромов | Средство для кишечного лаважа |
CA2880282C (en) * | 2012-07-27 | 2020-09-01 | Redhill Biopharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
CN105007915B (zh) | 2012-09-11 | 2018-09-28 | 诺金股份有限公司 | 包含peg和抗坏血酸的组合物 |
KR101659746B1 (ko) | 2014-01-28 | 2016-09-26 | 주식회사한국파마 | 황산염을 함유하는 장관 하제 조성물 및 이의 제조 방법 |
EA201692106A1 (ru) | 2014-04-29 | 2017-04-28 | КОЛОНАРИКОНСЕПТС ЭлЭлСи | Пищевые продукты, системы, способы и наборы для замены электролитов |
AU2016226380A1 (en) | 2015-03-02 | 2017-09-21 | Colonaryconcepts Llc | Compounds and methods for PEG metabolite and PEG breakdown product assays |
WO2017011430A1 (en) * | 2015-07-13 | 2017-01-19 | Halow George M | Bowel cleansing compositions and methods |
JP2018131396A (ja) * | 2017-02-14 | 2018-08-23 | 学校法人自治医科大学 | 経口腸管洗浄剤および大腸カプセル内視鏡用ブースター |
KR102005072B1 (ko) * | 2017-12-15 | 2019-07-29 | 주식회사 씨티씨바이오 | 장관 세척용 하제 조성물 |
KR102111094B1 (ko) | 2018-06-18 | 2020-05-14 | 주식회사 한국팜비오 | 무수황산나트륨, 황산칼륨, 무수황산마그네슘 및 시메티콘을 포함하는 장관하제 경구투여용 고형제제 조성물 |
CN115040512B (zh) * | 2022-07-28 | 2023-06-20 | 苏州中化药品工业有限公司 | 一种药物组合物及其制备方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3121663A (en) * | 1956-02-09 | 1964-02-18 | Plough Lab Inc | Carbon dioxide releasing laxative suppository |
US3202578A (en) * | 1957-09-27 | 1965-08-24 | Elder Paul B Co | Polymeric laxative composition and method of using same |
GB1459488A (en) * | 1974-03-19 | 1976-12-22 | Wyeth John & Brother Ltd | Piperazinedione derivatives |
US4321263A (en) * | 1980-09-30 | 1982-03-23 | Rowell Laboratories, Inc. | Psyllium compositions |
US4812311A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
AU6196786A (en) | 1985-08-01 | 1987-03-05 | Braintree Laboratories Inc. | Low-sodium laxative and lavage formulation |
US4849227A (en) * | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
US4828842A (en) * | 1986-09-16 | 1989-05-09 | L. Perrigo Company | Water dispersible compound |
US4999200A (en) * | 1987-12-09 | 1991-03-12 | Marion Laboratories | Psyllium tablet composition, method of manufacture and method of use |
JPH0816061B2 (ja) * | 1988-07-13 | 1996-02-21 | 森下ルセル株式会社 | 腸管洗浄液用組成物と腸管洗浄液 |
US5294451A (en) * | 1991-03-29 | 1994-03-15 | Curtice-Burns, Inc. | Fat substitute compositions having reduced laxative effects |
WO1997041838A1 (en) * | 1996-05-08 | 1997-11-13 | Aronchick Craig A | Non-aqueous colonic purgative formulations |
US5397573A (en) * | 1993-06-04 | 1995-03-14 | The Procter & Gamble Company | Laxative compositions |
US5516524A (en) * | 1993-12-20 | 1996-05-14 | The Procter & Gamble Company | Laxative compositions containing bulk fiber |
US5498425A (en) * | 1995-03-17 | 1996-03-12 | Block Drug Company, Inc. | Phosphosoda buffered saline laxative |
US5710183A (en) * | 1995-07-14 | 1998-01-20 | Halow; George M. | Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent |
FR2746643B1 (fr) * | 1996-04-01 | 1998-06-12 | Techni Pharma | Nouvelles compositions laxatives et leur procede de fabrication |
CA2221011C (en) * | 1996-11-13 | 2003-06-24 | C.B. Fleet Company, Inc. | A coated sodium phosphate bowel cleanser |
US6162464A (en) | 1997-03-31 | 2000-12-19 | Inkine Pharmaceutical, Inc. | Non-aqueous colonic purgative formulations |
US6048901A (en) * | 1999-04-20 | 2000-04-11 | Braintree Laboratories, Inc. | Method of reducing intestinal gas, cramping and anorectal irritation |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US6645481B1 (en) | 2000-09-28 | 2003-11-11 | Braintree Laboratories, Inc. | Method of achieving overnight laxation and control of bowel function |
US6946149B2 (en) | 2002-04-30 | 2005-09-20 | Braintree Laboratories, Inc. | Salt solution for colon cleansing |
US8361452B2 (en) | 2002-07-15 | 2013-01-29 | Halow George M | Bowel cleansing composition |
US20040071779A1 (en) | 2002-10-09 | 2004-04-15 | Keiser Dale Arthur | Gelled laxative compositions |
US7687075B2 (en) | 2003-11-19 | 2010-03-30 | Salix Pharmaceuticals, Ltd. | Colonic purgative composition with soluble binding agent |
-
2004
- 2004-11-16 US US10/988,693 patent/US7687075B2/en active Active
- 2004-11-17 CA CA2814523A patent/CA2814523C/en active Active
- 2004-11-17 CN CN2004800407012A patent/CN101087593B/zh active Active
- 2004-11-17 KR KR1020127003801A patent/KR101323628B1/ko active IP Right Grant
- 2004-11-17 KR KR1020137007695A patent/KR101495690B1/ko active IP Right Grant
- 2004-11-17 EP EP04819530.9A patent/EP1682098B1/en active Active
- 2004-11-17 AU AU2004292428A patent/AU2004292428B2/en active Active
- 2004-11-17 ES ES04819530.9T patent/ES2584866T3/es active Active
- 2004-11-17 CN CN201210119344.5A patent/CN102648980B/zh active Active
- 2004-11-17 BR BRPI0416702A patent/BRPI0416702B8/pt active IP Right Grant
- 2004-11-17 KR KR1020067011762A patent/KR20060114342A/ko not_active Application Discontinuation
- 2004-11-17 JP JP2006541302A patent/JP5329042B2/ja active Active
- 2004-11-17 WO PCT/US2004/038220 patent/WO2005051361A1/en active Application Filing
- 2004-11-17 BR BR122014001142A patent/BR122014001142B8/pt active IP Right Grant
- 2004-11-17 EP EP10180972.1A patent/EP2308476B1/en active Active
- 2004-11-17 CA CA2546637A patent/CA2546637C/en active Active
- 2004-11-17 KR KR1020117019045A patent/KR101268559B1/ko active IP Right Grant
- 2004-11-17 PL PL04819530.9T patent/PL1682098T3/pl unknown
- 2004-11-19 AR ARP040104289A patent/AR046651A1/es not_active Application Discontinuation
-
2008
- 2008-03-13 US US12/075,772 patent/US7718197B2/en active Active
-
2010
- 2010-01-20 US US12/690,384 patent/US8507009B2/en active Active
-
2011
- 2011-05-20 AU AU2011202346A patent/AU2011202346B2/en active Active
- 2011-06-14 JP JP2011132713A patent/JP5502807B2/ja active Active
-
2014
- 2014-01-17 JP JP2014007066A patent/JP2014065746A/ja not_active Withdrawn
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101874796A (zh) * | 2009-04-29 | 2010-11-03 | 田普森 | 一种治疗便秘的药物制剂及其制备方法 |
CN102283861A (zh) * | 2010-06-17 | 2011-12-21 | 杭州赛利药物研究所有限公司 | 氢氧化镁在制药中的用途以及氢氧化镁制剂和制备方法 |
CN102178694A (zh) * | 2011-05-06 | 2011-09-14 | 四川健能制药有限公司 | 磷酸钠盐液体制剂 |
US9919007B2 (en) | 2013-03-15 | 2018-03-20 | Braintree Laboratories, Inc. | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof |
CN105228634A (zh) * | 2013-05-17 | 2016-01-06 | 协和化学工业株式会社 | 用于大肠检查或手术的处理剂和处理方法 |
CN103585173A (zh) * | 2013-10-28 | 2014-02-19 | 王显著 | 含硫酸钠和匹可硫酸的药物组合物 |
CN103585173B (zh) * | 2013-10-28 | 2016-06-29 | 王显著 | 含硫酸钠和匹可硫酸的药物组合物 |
CN107787223A (zh) * | 2015-06-22 | 2018-03-09 | 西梯茜生命工学股份有限公司 | 肠道清洁用泻剂组合物 |
CN108601842A (zh) * | 2016-01-28 | 2018-09-28 | 西梯茜生命工学股份有限公司 | 泻药组合物 |
US10143656B1 (en) | 2017-08-04 | 2018-12-04 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
US11033498B2 (en) | 2017-08-04 | 2021-06-15 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
US11638697B2 (en) | 2017-08-04 | 2023-05-02 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
CN112386577A (zh) * | 2019-08-16 | 2021-02-23 | 北京天衡药物研究院有限公司 | 一种治疗便秘的组合物 |
CN112386577B (zh) * | 2019-08-16 | 2024-01-23 | 北京天衡药物研究院有限公司 | 一种治疗便秘的组合物 |
CN112587498A (zh) * | 2020-12-29 | 2021-04-02 | 哈尔滨瀚钧现代制药有限公司 | 多库酯钠丹蒽醌及其制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101087593B (zh) | 含可溶性粘合剂的结肠泻药组成物 | |
JP5871830B2 (ja) | ポリエチレングリコールの結腸の下剤組成物 | |
JPH03206048A (ja) | 胃腸の苦痛を治療する製薬学的組成物 | |
Ade et al. | Effect of Aragwadha (Cassia fistula Linn.) Granules on Vibandh (Constipation) | |
AU2015221520B2 (en) | Colonic purgative composition with soluble binding agent | |
AU2012202628B2 (en) | Colonic purgative composition with soluble binding agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1109079 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CI01 | Publication of corrected invention patent application |
Correction item: Priority Correct: 60/523,142 2003.11.19 US Number: 29 Volume: 29 |
|
CI03 | Correction of invention patent |
Correction item: Priority Correct: 60/523,142 2003.11.19 US Number: 29 Page: The title page Volume: 29 |
|
ERR | Gazette correction |
Free format text: CORRECT: PRIORITY; FROM: NONE TO: 60/523,142 2003.11.19 US |
|
RECT | Rectification | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1109079 Country of ref document: HK |